Mirum Pharmaceuticals, Inc.
MIRM
Rangering i aksjer
#3223
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Aksjekurs
$85.12
Markedsverdi
$5.53B
Endring (1 dag)
3.50%
Endring (1 år)
16.55%
Land
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
P/B-forhold for Mirum Pharmaceuticals, Inc. (MIRM)
P/B-forhold per October 2026 TTM: -486.22
Ifølge Mirum Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) -486.22. Ved slutten av 2023 hadde selskapet et P/B-forhold på 4.85.
P/B-historikk for Mirum Pharmaceuticals, Inc. fra 2018 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | -486.22 | -5,682.34% |
| 2024 | 8.71 | 79.44% |
| 2023 | 4.85 | -388.93% |
| 2022 | -1.68 | -141.75% |
| 2021 | 4.02 | -258.02% |
| 2020 | -2.55 | -68.43% |
| 2019 | -8.06 | -72.59% |
| 2018 | -29.42 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -101.29% |
US
|
|
| 13.2547 | -102.73% |
US
|
|
| 4.208 | -100.87% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -101.27% |
NL
|
